Inhibition of proprotein convertase subtilisin/kexin type 9: A novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia

Chinese Journal of Integrative Medicine

Volumn 21, Issue 2, 2015, Pages 132-138

  Liu, De liang ^a   Xu, Li jun ^a   Dong, Hui ^a   Chen, Guang ^a   Huang, Zhao yi ^a   Zou, Xin ^a   Wang, Kai fu ^a   Luo, Yun huan ^a   Lu, Fu er ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

8 hydroxy dihydroberberine; hyperlipidemia; low density lipoprotein receptor; rat

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; BERBERINE; DIHYDROBERBERINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; PCSK9 PROTEIN, RAT; SERINE PROTEINASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; DRUG EFFECTS; HYPERLIPIDEMIAS; LIVER; MALE; METABOLISM; WISTAR RAT;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; BERBERINE; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYPERLIPIDEMIAS; LIPIDS; LIVER; MALE; RATS, WISTAR; RECEPTORS, LDL; SERINE ENDOPEPTIDASES; STEROL REGULATORY ELEMENT BINDING PROTEIN 2;

EID: 84939895194     PISSN: 16720415     EISSN: 19930402     Source Type: Journal    
DOI: 10.1007/s11655-014-1775-1     Document Type: Article

References (20)

1. Prasad K, Kalra J. Oxygen free radicals and hypercholesterolemic atherosclerosis: effect of vitamin E. Am Heart J 1993;125:958–1173.
2. Deepa PR, Varalakshmi P. Atheroprotective effect of exogenous heparin-derivative treatment on the aortic disturbances and lipoprotein oxidation in hypercholesterolemic diet fed rats. Clin Chim Acta 2005;355:119–130.
3. Glass CK, Witztum JL. Atherosclerosis, the road ahead. Cell 2001;104:503–516.
4. He XD, Wu HH, Lou YJ. Combined effects of atorvastatin and soybean isoflavones on hypercholesterolemia and lipoprotein metabolism. Chin J Pharmacol Toxicity (Chin) 2006;20:381–386.
5. Endo A, Kuroda M, Tanzawa Y. Competitive inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase by ML-236A and ML-236B, fungal metabolites having hypocholesterolemic activity. 1976. Atheroscler Suppl 2004;5:39–42.
6. Endo A. The discovery and development of HMG-CoA reductase inhibitors. Lipid Res 2003;33:1569–1582.
7. Sewright KA, Clarkson PM, Thompson PD. Statin myopathy: incidence, risk factors, and pathophysiology. Curr Atheroscler Rep 2007;9:389–396.
8. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 2003;289:1681–1690.
9. Sinzinger H, O’Grady J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004;57:525–528.
10. Thompson PD, Zmuda JM, Domalik LJ, Zimet RJ, Staggers J, Guyton JR. Lovastatin increases exercise-induced skeletal muscle injury. Metabolism 1997;46:1206–1210.
11. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 2004;10:1344–1351.
12. Berbeine derivatives and their producing methods, applications and their combinative usages. Patent number: 2006100194924.
13. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med 1984;76:4–12.
14. Duncan EA, Davé UP, Sakai J, Goldstein JL, Brown MS. Second-site cleavage in sterol regulatory element-binding protein occurs at transmembrane junction as determined by cysteinepanning. Biol Chem 1998;273:17801–17809.
15. Robinet P, Védie B, Chironi G, Gariépy J, Simon A, Moatti N, et al. Characterization of polymorphic structure of SREBP-2 gene: role in atherosclerosis. Atherosclerosis 2003;168:381–387.
16. Raghow R, Yellaturu C, Deng X, Park EA, Elam MB. SREBPs: the crossroads of physiological and pathological lipid homeostasis. Trends Endocrinol Metab 2008;19:65–73.
17. Miserez AR, Muller PY, Barella L, Barella S, Staehelin HB, Leitersdorf E, et al. Sterol-regulatory elementbinding protein (SREBP)-2 contributes to polygenic hypercholesterolaemia. Atherosclerosis 2002;164:15–26.
18. Zhang R. Research progress on low-density lipoprotein receptor and its regulating mechanism. Foreign Med Sci: Geriatr (Chin) 2009;3:29–30.
19. Marianne A, Mathilde V, Jean-Pierre R, Delphine A, Khadija O, Martine D, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154–156.
20. Cohen J, Pertsemlidis A, Kotowski IK, Graham R, Garcia CK, Hobbs HH. Low LDL-cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005;37:161–165.